Turner Jonathan M, Connolly Kristie L, Aberman Kate E, Fonseca Joseph C, Singh Avinash, Jerse Ann E, Nicholas Robert A, Davies Christopher
Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina 29425, United States.
Department of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland 20814, United States.
ACS Infect Dis. 2021 Feb 12;7(2):293-308. doi: 10.1021/acsinfecdis.0c00400. Epub 2021 Feb 3.
The increasing prevalence of strains exhibiting decreased susceptibility to extended-spectrum cephalosporins (ESCs) presents a challenge for the successful treatment of gonorrhea infections. To address this challenge, we evaluated a panel of 23 cephalosporins against penicillin-binding protein 2 (PBP2) from the ESC-resistant (ESC) strain H041 to determine which molecular features are important for antimicrobial activity. Structure-activity relationships (SARs) developed from acylation rate constants against PBP2 and antimicrobial susceptibilities against the H041 strain of , and interpreted against docking models, reveal that cephalosporins possessing large, lipophilic R side chains and electronegative R side chains with planar groups are associated with higher acylation rates against PBP2, but also that these same amphipathic features can lower antimicrobial activity. Based on these studies, we tested cefoperazone, one of the most effective ESCs for targeting PBP2, in the female mouse model infected with H041 and showed that it was equally or more effective than ceftriaxone or gentamicin for clearing infections. Taken together, our results reveal that two U.S. Food and Drug Administration (FDA)-approved agents (cefoperazone, ceftaroline) and one FDA-qualified infectious disease product (ceftobiprole) have potential as first-line treatments for gonorrhea and provide a framework for the future design of cephalosporins with improved activity against ESC-resistant .
对超广谱头孢菌素(ESCs)敏感性降低的菌株日益增多,这给淋病感染的成功治疗带来了挑战。为应对这一挑战,我们评估了一组23种头孢菌素对ESCs耐药(ESC)菌株H041的青霉素结合蛋白2(PBP2)的作用,以确定哪些分子特征对抗菌活性很重要。根据针对PBP2的酰化速率常数以及对H041菌株的抗菌敏感性建立的构效关系(SARs),并结合对接模型进行解读,结果表明,具有大的亲脂性R侧链以及带有平面基团的电负性R侧链的头孢菌素与针对PBP2的较高酰化速率相关,但同样这些两亲性特征也可能降低抗菌活性。基于这些研究,我们在感染H041的雌性小鼠模型中测试了头孢哌酮(靶向PBP2最有效的ESCs之一),结果表明它在清除感染方面与头孢曲松或庆大霉素效果相当或更有效。综上所述,我们的结果表明,两种美国食品药品监督管理局(FDA)批准的药物(头孢哌酮、头孢洛林)和一种FDA合格的传染病产品(头孢比普)有潜力作为淋病的一线治疗药物,并为未来设计对ESC耐药菌活性更高的头孢菌素提供了一个框架。